Friday 6 November 2026 Export IDYA’s income statement to Excel — free account

IDEAYA Biosciences, Inc.

IDEAYA Biosciences, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $218.7 million, up 3,024.4% from fiscal 2024.

Revenue: −95.1%
EPS: −190.5%
Free cash flow: −165.9%

Quarter to September 2026, against a year earlier

Insider buying

30.85 0.20 +0.65%

Follow IDYA

Alert me

Market cap: $3.0B
P/E: 0.0×
Fwd P/E: −6.9×
Dividend yield: —
F-score: 4/9
Altman Z: 20.70
Beneish M: n/a
Dividend safety: n/a

Overview

Insider Decisions last twelve months

Bought, $m 1.65

Sold, $m 1.37

Trades a month
	Jan 26			Apr 26			Jul 26			Oct 26
Buy	—	—	—	1	—	—	—	—	—	—	—	—
Sell	—	—	—	—	—	—	—	1	—	—	1	—

Insider Ownership 12.50%

Capital & Financial Ratios $m

Size

Market Cap 2,960.00

Revenue ttm 36.54

Net income ttm (420.01)

Free cash flow ttm (349.80)

Net debt Q (838.54)

Valuation

P/E 0.00

Forward P/E (6.89)

Price / sales 86.70

Forward P/S Powerpack

Price / FCF 0.00

Price / book 2.90

Financial health

Current ratio Q 9.04

Debt / equity Q 0.00

Interest coverage Q —

Growth

Revenue growth Q −95.07%

Operating income growth Q −226.91%

EPS, this year −268.34%

EPS, next year A +7.59%

Revenue, next year A −81.25%

EPS, past 5 yrs —

EPS, next 5 yrs A −29.51%

Green and red mark values outside typical ranges; (Q) is the latest quarter, (A) analysts’ estimates. How we judge →

Valuation vs history

EV/Sales, ten years

P/S against its own 10 years 75.02%

10-year low 10-year high

P/B against its own 10 years 72.58%

10-year low 10-year high

EV/Sales against its own 10 years 78.44%

10-year low 10-year high

Dividends

Yield: —
Annual rate: —
Payout ratio: —

Assets vs Liabilities $m

	2023	2024	2025	Q'26
Cash	525	676	639	839
Receivables	0	0	—	—
Inventory	—	—	—	—
Other	—	—	6	10
	533	690	667	872

	2023	2024	2025	Q'26
Payables	7	15	18	22
ST’ Debt	—	—	—	—
Other	—	—	—	—
	27	46	59	96

Compound Annual Growth %

	10y	5y	3y
Sales	—	62.11%	62.54%
Cash Flow	—	0.00%	0.00%
Earnings	—	0.00%	0.00%
Book Value	—	38.84%	43.05%

Earnings Trends EPS, adjusted, against the consensus

Q3 FY26 Estimate −1.26 Actual −1.22

−1.31 −1.20 −1.10 −1.00 −0.89

Q4 FY25 Beat +0.09

Q1 FY26 Miss −0.04

Q2 FY26 Miss −0.04

Q3 FY26 Beat +0.04

Q4 FY26 — Feb 16

Earnings per share against the consensus, by quarter
Quarter	Estimate	Reported	Result
Q4 FY25	−1.03	−0.94	Beat by 0.09
Q1 FY26	−1.07	−1.11	Miss by 0.04
Q2 FY26	−1.18	−1.22	Miss by 0.04
Q3 FY26	−1.26	−1.22	Beat by 0.04
Q4 FY26	−1.13	—	Reports 16 February 2027

EPS $

	Mar	Jun	Sep	Dec	Year
’26	(1.11)	(1.22)	(1.22)	—	—
’25	(0.82)	(0.88)	1.33	(0.94)	(1.28)
’24	(0.53)	(0.68)	(0.60)	(1.49)	(3.36)
’23	(0.49)	(0.50)	(0.46)	(0.52)	(1.96)
’22	(0.36)	(0.57)	0.04	(0.50)	(1.42)
’21	(0.28)	(0.33)	(0.31)	(0.47)	(1.41)
’20	(0.59)	(0.59)	(0.17)	(0.18)	(1.40)

Fiscal quarters ending in the months shown.

Revenue $m

	Mar	Jun	Sep	Dec	Year
’26	7	9	10	—	—
’25	—	—	208	11	219
’24	—	—	—	—	7
’23	8	4	8	4	23
’22	11	6	30	4	51
’21	7	9	9	3	28

Fiscal quarters ending in the months shown.

Operating Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	(75)	(88)	(93)	—	—
’25	(60)	(62)	142	(90)	(71)
’24	(44)	(33)	(49)	(122)	(248)
’23	(28)	(33)	(30)	(24)	(115)
’22	(20)	(20)	(24)	(23)	(87)
’21	(14)	(13)	(12)	(17)	(56)
’20	(10)	(14)	90	(12)	55

Fiscal quarters ending in the months shown.

Free Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	(76)	(89)	(94)	—	—
’25	(62)	(63)	142	(91)	(73)
’24	(45)	(34)	(50)	(123)	(251)
’23	(28)	(34)	(31)	(25)	(118)
’22	(20)	(22)	(25)	(23)	(91)
’21	(15)	(14)	(13)	(17)	(58)
’20	(10)	(14)	90	(12)	55

Fiscal quarters ending in the months shown.

Group	Line	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025	TTM Sep ’26	Trend	10 yrs	2026e	2027e	2028e	Next 3/yr
													Ten-year view		Analyst estimates Powerpack
Income, $m
Income, $m	Revenue	—	—	—	—	20	28	51	23	7	219	37		+62.1%	41	118	262	+6.3%
	Gross margin, %	—	0.00	0.00	0.00	100.00	100.00	100.00	100.00	100.00	100.00	100.00		+100.0 pt	Powerpack IDEAYA Biosciences, Inc.’s next three years, line by line Analysts expect revenue to grow 6.3% a year to 2028 — slower than the 62.1% of the last 5 years. See the consensus for every other line: earnings, margins, cash flow, valuation and returns. Unlock estimates Try Powerpack free for 7 days, then $99 / year ($8.25 a month). Cancel any time. Also in Powerpack: every quarter, Excel exports, API & MCP access. Compare plans
	EBT	—	(12)	(34)	(42)	(34)	(50)	(59)	(113)	(274)	(114)	(420)		+32.6%
	EBT margin, %	—	0.00	0.00	0.00	(176.55)	(178.10)	(115.17)	(483.05)	(3,921.10)	(51.99)	(1,149.62)		(52.0) pt
	Net income	—	(12)	(34)	(42)	(34)	(50)	(59)	(113)	(274)	(114)	(420)		+32.6%
Per share, $
Per share, $	Revenue	—	0.00	0.00	0.00	0.79	0.79	1.23	0.41	0.09	2.47	0.35		n/m
	Earnings	—	(17.07)	(35.93)	(3.36)	(1.40)	(1.41)	(1.42)	(1.96)	(3.36)	(1.28)	(4.49)		(27.7%)
	Cash flow	—	(17.59)	(28.89)	(3.15)	2.24	(1.58)	(2.10)	(2.00)	(3.03)	(0.80)	(3.37)		(32.0%)
	Capex	—	(2.53)	(1.79)	(0.11)	(0.02)	(0.07)	(0.08)	(0.04)	(0.05)	(0.03)	(0.02)		(43.4%)
	Free cash flow	—	(20.12)	(30.68)	(3.25)	2.22	(1.66)	(2.19)	(2.04)	(3.08)	(0.83)	(3.40)		(32.9%)
	Book value	—	0.00	(51.20)	8.03	8.02	8.55	8.43	10.80	12.97	11.56	10.61		n/m
	Shares, m	—	1	1	12	25	35	41	58	82	88	93		+83.3%
Valuation, ×
Valuation, ×	P/E	—	—	—	—	0.00	0.00	0.00	0.00	0.00	0.00	0.00		0.0
	P/S	—	—	—	—	0.00	29.83	14.14	86.63	89.76	13.26	86.70		38.9
	P/B	—	—	—	—	1.75	2.76	2.06	3.26	1.98	2.99	2.90		2.5
	EV/Sales	—	—	—	—	0.00	20.99	6.98	64.18	60.84	10.49	63.75		27.2
	EV/FCF	—	—	—	—	1.14	(10.04)	(3.92)	(12.76)	(5.66)	(32.93)	(6.66)		(10.7)
Cash, $m
Cash, $m	Operating cash flow	—	(12)	(28)	(39)	55	(56)	(87)	(115)	(248)	(71)	(347)		+24.6%
	Capex	—	(2)	(2)	(1)	0	(3)	(3)	(2)	(4)	(2)	(2)		+3.8%
	Free cash flow	—	(14)	(29)	(41)	55	(58)	(91)	(118)	(251)	(73)	(350)		+23.0%
Balance, $m
Balance, $m	Working capital	—	11	85	95	250	206	339	506	644	608	776		+64.9%
	Net debt	—	(13)	(90)	(99)	(284)	(247)	(365)	(525)	(676)	(639)	(839)		+62.5%
	Shareholders’ equity	—	—	(49)	100	198	302	349	621	1,059	1,023	1,092		n/m
Returns, %
Returns, %	ROA	—	(20.81)	(71.15)	(40.06)	(16.77)	(14.64)	(15.25)	(21.78)	(30.95)	(10.18)	(34.98)		+10.6 pt
	ROIC	—	0.00	0.00	(1,916.16)	0.00	(57.39)	0.00	(87.54)	(53.38)	(25.96)	(114.15)		(26.0) pt
	ROE	—	36.68	106.19	(163.16)	(23.10)	(19.91)	(18.02)	(23.28)	(32.67)	(10.92)	(38.46)		(47.6) pt
People
People	Employees	—	—	58	47	62	81	103	124	131	145	—		+14.0%
	Revenue/emp, $m	—	—	0.00	0.00	0.32	0.34	0.49	0.19	0.05	1.51	—		n/m

Negative figures in brackets.

estimates

All 10 years →

Fiscal years to Dec 2025 · latest quarter Sep 2026 · fundamentals updated 5 Nov 2026

Company	Market cap	P/E	Fwd P/E	Revenue growth (Q)	EPS growth (Q)	FCF growth (Q)	Gross margin (Q)	EBIT margin (Q)	Compare
TARS Tarsus Pharmaceuticals, Inc.	$3.3B	— (loss-making)	— (loss-making)	+63.92% (above 0%: growing)	n/m	−144.14% (below 0%: shrinking)	92.86%	(340.29%)	Compare
ELVN Enliven Therapeutics, Inc.	$3.3B	— (loss-making)	—	—	n/m	−8.34% (below 0%: shrinking)	0.00%	0.00%	Compare
DYN Dyne Therapeutics, Inc.	$3.2B	— (loss-making)	—	—	n/m	−39.08% (below 0%: shrinking)	0.00%	0.00%	Compare
VRDN Viridian Therapeutics, Inc.	$3.2B	— (loss-making)	— (loss-making)	−63.51% (below 0%: shrinking)	n/m	−9.92% (below 0%: shrinking)	100.00%	(401.82%)	Compare
TLX Telix Pharmaceuticals Limited	$3.2B	—	—	—	—	−44.78% (below 0%: shrinking)	—	—	Compare
DNLI Denali Therapeutics Inc.	$3.2B	— (loss-making)	— (loss-making)	−93.96% (below 0%: shrinking)	n/m	−11.83% (below 0%: shrinking)	98.92%	(712.97%)	Compare
CELC Celcuity, Inc.	$3.1B	— (loss-making)	—	—	n/m	−53.27% (below 0%: shrinking)	0.00%	0.00%	Compare
IDYA IDEAYA Biosciences, Inc.	$3.0B	— (loss-making)	— (loss-making)	−95.07% (below 0%: shrinking)	n/m	−165.94% (below 0%: shrinking)	100.00%	(1,343.80%)
BEAM Beam Therapeutics Inc.	$2.7B	— (loss-making)	— (loss-making)	−96.83% (below 0%: shrinking)	n/m	−29.45% (below 0%: shrinking)	100.00%	(46,033.22%)	Compare
Median of peers	$3.2B	—	—	−78.73%	—	−34.26%	92.86%	(340.29%)

All 621 Biotechnology stocks →

Pay and ownership Proxy statement filed 29 April 2026

Chief executive’s pay

Year	Total pay	Actually paid	$100 invested
2025	9.51m	15.70m	246.93
2024	16.93m	5.81m	183.57
2023	6.00m	15.72m	254.14
2022	3.33m	1.79m	129.79
2021	3.85m	7.28m	168.86

Ownership

Directors and executive officers, together 4.70%

FMR LLC 14.40%

BlackRock, Inc. 8.10%

Janus Henderson Group plc 7.30%

Capital Research Global Investors 6.00%

Total pay is as the Summary Compensation Table states it; actually paid revalues the year’s share awards at its end, as the SEC’s pay-versus-performance rule asks. $100 invested is what $100 in the company’s shares at the start of the earliest year shown was worth at each year’s end. Ownership is the proxy’s own table: the directors and officers as a group, and every holder of 5% or more. Read the proxy statement

IDEAYA Biosciences, Inc. (IDYA) Latest News

3 Nov

Impact 4 · 6:00 AM · PR Newswire

IDEAYA Biosciences Reports Financial Results for the Third Quarter 2026 and Provides a Business Update

28 Oct

Impact 3 · 9:00 AM · Zacks

Earnings Preview: Acadia Pharmaceuticals (ACAD) Q3 Earnings Expected to Decline

27 Oct

Impact 3 · 9:00 AM · Zacks

IDEAYA Biosciences, Inc. (IDYA) Expected to Beat Earnings Estimates: Can the Stock Move Higher?

23 Oct

Impact 4 · 6:00 AM · PR Newswire

IDE849 (SHR-4849) DLL3 TOP1 ADC Updated Phase 1 Results at ESMO 2026 Demonstrates Promising Anti-Tumor Activity and Preliminary Overall Survival Results in Relapsed Small Cell Lung Cancer and Neuroendocrine Carcinomas

21 Oct

Impact 3 · 12:30 PM · Business Wire

William Blair Expands Biotech Research as Veteran Analyst Alethia Young Initiates Coverage

19 Oct

Impact 4 · 6:00 AM · PR Newswire

IDEAYA Biosciences and Servier Announce Data From Three Clinical Trials at ESMO 2026 Supporting the Potential of Darovasertib to Become a Foundational New Therapy for Patients Across the Treatment Journey of Uveal Melanoma

8 Oct

Impact 3 · 1:18 PM · Simply Wall St.

IDEAYA Biosciences (IDYA) Rethinks Its R And D Leadership As Undervaluation Questions Grow

28 Sep

Impact 3 · 6:00 AM · PR Newswire

IDEAYA Biosciences Announces the Promotion of Dr. Michael White to President, Research and Development

25 Sep

Impact 4 · 5:42 AM

Can IDEAYA Biosciences (IDYA) Turn Uncharted Oncology Territory Into Commercial Gold?

9 Sep

Impact 4 · 6:00 AM

IDEAYA Biosciences and Servier Announce First Patient Dosed in OptimUM-11 Global Phase 3 Registrational Trial of Darovasertib and Crizotinib as Adjuvant Therapy for Subjects with Uveal Melanoma

31 Aug

Impact 4 · 6:00 AM

IDEAYA Biosciences Announces Successful FDA Type C Meeting for IDE849, DLL3 TOP1 ADC, on Phase 3 Registrational Trial Design for Potential Accelerated and Full Approval in Extensive Stage Small Cell Lung Cancer

19 Aug

Impact 4 · 6:00 AM

IDEAYA Biosciences Announces Clinical Collaboration with Genentech in MTAP-Deleted KRAS G12D-Mutant Pancreatic Cancer

5 Aug

Impact 4 · 4:12 PM

The Bull Case For IDEAYA Biosciences (IDYA) Could Change Following Wider Loss And New Roche Partnership

4 Aug

Impact 3 · 6:00 AM earnings

IDEAYA Biosciences Reports Second Quarter 2026 Financial Results and Provides Business Update

27 Jul

Impact 4 · 6:00 AM

IDEAYA Biosciences Announces IDE892, a Potential Best-in-Class MTA-Cooperative PRMT5 Inhibitor, Initiates Part 2 Monotherapy Expansion in the Phase 1/2 Study in MTAP-Deleted Pancreatic and Lung Cancers

15 Jun

Impact 3 · 6:00 AM

IDEAYA Biosciences Announces IDE892, a Potential Best-in-Class MTA-Cooperative PRMT5 Inhibitor, Initiates a Phase 1/2 Clinical Combination Study in MTAP-Deleted Pancreatic and Lung Cancers

11 Jun

Impact 4 · 6:20 AM · Insider Monkey

Ideaya Biosciences (IDYA) Forms Clinical Partnership With Roche for IDE892 Efficacy Study

8 Jun

Impact 3 · 10:22 PM · PR Newswire

IDEAYA Announces Pricing of $300 Million Offering of Common Stock and Pre-Funded Warrants

Impact 3 · 4:01 PM · PR Newswire

IDEAYA Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants

6 Jun

Impact 5 · 6:08 AM · Simply Wall St.

What IDEAYA Biosciences (IDYA)'s Darovasertib Phase 2/3 Win and Roche Deal Mean For Shareholders

3 Jun

Impact 4 · 6:00 AM · PR Newswire

IDEAYA Biosciences Announces Clinical Collaboration with Roche in MTAP-Deleted RAS-Mutant Pancreatic Cancer

1 Jun

Impact 4 · 11:00 AM · PR Newswire

IDEAYA Biosciences and Servier Provide Complete Data from Phase 2/3 Registrational OptimUM-02 Trial of the Darovasertib Combination in First Line HLA*A2:01 Negative Metastatic Uveal Melanoma in a Late-Breaking Oral Presentation at ASCO

26 May

Impact 4 · 7:03 PM · MarketBeat

IDEAYA Biosciences Spotlights Darovasertib Win, FDA Review Path at Oncology Summit

25 May

Impact 4 · 7:07 AM · MarketBeat

IDEAYA Biosciences Eyes Busy 2026 as Darovasertib Advances Toward FDA Filing

18 May

Impact 4 · 12:05 AM · MarketBeat

IDEAYA Biosciences Says Melanoma Drug on Track for NDA After Strong Trial Data

7 May

Impact 5 · 3:17 PM · Simply Wall St.

Assessing IDEAYA Biosciences (IDYA) Valuation After Positive Darovasertib Phase 2/3 Results And FDA Real-Time Review

5 May

Impact 3 · 7:10 AM · Zacks

IDEAYA Biosciences, Inc. (IDYA) Reports Q1 Loss, Misses Revenue Estimates

Impact 3 · 6:00 AM · PR Newswire

IDEAYA Biosciences Reports First Quarter 2026 Financial Results and Provides Business Update

3 May

Impact 3 · 2:41 PM · Insider Monkey

Is IDEAYA Biosciences, Inc. (IDYA) A Good Stock To Buy Now?

30 Apr

Impact 4 · 6:00 AM · PR Newswire

IDEAYA Biosciences to Initiate New Drug Application Submission from the Darovasertib OptimUM-02 Trial under the Oncology Center of Excellence Real-time Oncology Review (RTOR) Program

Insider Decisions last twelve months

Capital & Financial Ratios $m

Valuation vs history

Dividends

Assets vs Liabilities $m

Compound Annual Growth %

Earnings Trends EPS, adjusted, against the consensus

EPS $

Revenue $m

Operating Cash Flow $m

Free Cash Flow $m

Target Price Range

Recommendation Rating

Ten years at a glance Fiscal years to December

IDEAYA Biosciences, Inc. vs peers in Biotechnology (Q) = latest quarter vs a year earlier

Pay and ownership Proxy statement filed 29 April 2026

Chief executive’s pay

Ownership

IDEAYA Biosciences, Inc. (IDYA) Latest News

3 Nov

28 Oct

27 Oct

23 Oct

21 Oct

19 Oct

8 Oct

28 Sep

25 Sep

9 Sep

31 Aug

19 Aug

5 Aug

4 Aug

27 Jul

15 Jun

11 Jun

8 Jun

6 Jun

3 Jun

1 Jun

26 May

25 May

18 May

7 May

5 May

3 May

30 Apr

IDYA metrics, ten years each

Stockrow Weekly